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Abstract: Despite of vast improvements in treatment, myocardial infarction often leads to heart failure (HF) which re-
mains the leading cause of death in developed countries. Other than heart transplantation, therapeutic options have a lim-
ited role in improving out comes in patients with severe HF. It is therefore no surprise that cardiac cell therapy has raised 
many hopes as a novel therapeutic approach aimed at cardiac myocyte replacement/regeneration termed “cellular cardio-
myoplasty”. However, the ideal source, cell type, critical cell number, and mode of application for optimal therapeutic ef-
fect have not been defined thus far. Recent observations of the beneficial effect of cell transplantation in animal experi-
ments have generated tremendous excitement and stimulated clinical studies suggesting that this approach is feasible, safe, 
and potentially effective in humans. Cell-based myocardial regeneration is currently being explored for a wide range of 
cardiac disease states, including acute and chronic ischemic myocardial damage, cardiomyopathy and as biological heart 
pacemakers. The main purpose of this article is to review recent literature on the use of various cells for the examination 
of their in vitro cardiogenic potential and their in vivo capacity to engraft and improve the functional properties of the in-
farcted heart. 
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INTRODUCTION 
  Heart failure (HF) is a major and growing public health 
problem in the United States. Approximately 5 million pa-
tients have HF, and over 550,000 patients are diagnosed with 
HF for the first time each year [1]. The number of HF deaths 
has increased steadily despite advances in treatment due in 
part to the better treatment and “salvage” of dysfunctional 
cardiac tissue in patients with acute myocardial infarction 
(AMI) [1]. This situation is expected to become worse, with 
a sharp increase in coronary vascular disease (CVD) in de-
veloping countries along with aging world population and it 
is predicted that 25 million CVD deaths will occur world-
wide by 2020 and reach pandemic proportion as projected by 
the World Health Organization (WHO) [2]. 
  The two primary treatment options available for ad-
vanced HF are pharmacologic therapy and cardiac transplan-
tation [3]. Advances in medical therapy have had an impor-
tant impact on symptom status and short-term survival of 
patients with moderate to severe HF. The mainstay life-
saving drugs are angiotensin-converting enzyme (ACE) in-
hibitors and beta-blockers. Additional benefits are obtained 
when angiotensin-receptor blockers or aldosterone antago-
nists are added [4]. Existing pharmacologic agents have met 
with only moderate success in patients with class IV HF, and 
the 1-year survival rate is only 40–50% [5]. Heart transplan-
tation remains the treatment modality with the best outcome 
with 5-year survival rates of around 65%; however, it is lim-
ited by current shortage of donor organs [6]. The success of 
cardiac transplantation remains further limited by the com-
plications of long-term immunosuppression and the devel-
opment of allograft CAD. A variety of circulatory support  
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devices have been developed and are being used as bridge to 
transplant and more recently for destination therapy in pa-
tients experiencing end-stage HF who are ineligible for 
transplantation. The Randomized Evaluation of Mechanical 
Assistance for Treatment of Congestive Heart failure (RE-
MATCH) trial explored the use of left ventricular assist de-
vices as permanent implants and showed an increase median 
survival by 7.4 months and improved functional status in 
comparison with medical management in end-stage HF pa-
tients. Though shown to be beneficial, they have high device 
failure rate and numerous complications, mainly infections 
and bleeding as a result of necessary anticoagulant therapy 
[7, 8]. 
  Myocardial infarction (MI), one of the major contributor 
of HF occurs in approximately 1 million patients annually. 
Despite optimal medical therapy and aggressive revasculari-
zation strategies, MI with left ventricular dysfunction is a 
lethal condition for 25% of patients over 3 years after the 
event [9]. Current clinical interventions to minimize these 
devastating effects range from acute percutaneous coronary 
intervention (PCI) to administration of drugs such as beta-
blockers, which inhibit neurohormonal activation or ACE 
inhibitors which prevent activation of the renin-angiotensin 
system. However, these therapeutic measures are not suffi-
cient to prevent left ventricular remodeling and subsequent 
development of HF. 
  Cell transplantation is an area of growing interest in 
clinical cardiology as a potential means of treating patients 
with MI and/or HF. For HF, the goal of cell therapy is re-
placement of akinetic scar tissue by viable myocardium in 
hopes of improving cardiac function along with inhibition of 
the remodeling process. For MI, the target is to prevent HF 
by either rescuing the host myocardium or regenerating car-
diac cells. Both for the clinician and to the public, the con-
cept of not only preventing the progression and consequence 
of disease but reversing the disease process by enhancing Cardiac Cell Therapy  Current Cardiology Reviews, 2008, Vol. 4, No. 2    73
repair and regeneration of damaged tissues has introduced a 
new and exciting paradigm to treat cardiovascular disease. 
  Therefore, the main purpose of this article is to review 
recent literature on the use of cells for the examination of 
their in vitro cardiogenic potential and their in vivo capacity 
to graft and improve the functional properties of the heart. 
CELLULAR CARDIOMYOPLASTY  
  Cellular cardiomyoplasty involves myogenic cell grafting 
within the myocardium to limit any consequences from the 
loss of contractile function of a damaged left ventricle (LV) 
[10, 11]. Cell-based cardiac repair offers the promise of re-
generating damaged myocardium by rebuilding the injured 
heart from its component parts. Ideally, transplanted cells 
would mimic the lost myocytes morphologically and func-
tionally, with the ability to contract and to establish electrical 
connectivity with the native myocardial cells. 
Definition of Stem Cells 
  Stem cells are undifferentiated tissue progenitor cells that 
can proliferate and are defined by their ability to self renew 
and to form one or more differentiated cell types [12-14]. 
They can be categorized anatomically, functionally, or by 
cell surface markers, transcription factors, and the proteins 
they express. Different populations of stem cells are distin-
guished by the types of specialized cells that they generate. 
One clear division of the stem cell family is between those 
isolated from the embryo, known as embryonic stem cells 
(ESC), and those in adult somatic tissue known as adult stem 
cells. Within these categories, stem cells can be further di-
vided according to the number of differentiated cell types 
they can produce. Totipotent stem cells are able to form all 
fully differentiated cells of the body and trophoblastic cells 
of the placenta. The embryo, zygote, and the immediate de-
scendants of the first two cell divisions are the only cells 
considered to be totipotent [15]. Pluripotent cells can differ-
entiate into almost all cells that arise from the three germ 
layers, but are unable to give rise to the placenta and sup-
porting structures. At around 5 days after fertilization, ESC 
that form the inner cell mass of the blastocyst are considered 
pluripotent. Multipotent stem cells are capable of producing 
a small range of differentiated cell lineages appropriate to 
their location and are usually found in adult tissues. Stem 
cells with the least potential for differentiation are termed 
unipotent. 
POTENTIAL SOURCES - PRESENT AND FUTURE 
CELL TYPES 
  A variety of stem and progenitor cell populations could 
be used for cardiac repair. Each cell type has its own profile 
of advantages, limitations, and practicability issues in spe-
cific clinical settings. Studies comparing distinct cell types 
are scarce. The first clinically relevant cells to be proposed 
as a surrogate for cardiomyocytes were skeletal muscle 
myoblasts. Bone marrow which is easily accessible is, at 
present, the most frequent source of cells used for clinical 
cardiac repair [16] Fig. (1). It contains a complex assortment 
of progenitor cells, including hematopoietic stem cells 
(HSC), mesenchymal stem cells (MSC) [17], and multipo-
tential adult progenitor cells (MAPC), a subset of MSC [18]. 
Endothelial progenitor cells (EPC) are isolated from periph-
eral blood and many times are expanded in culture in ‘endo-
thelium-specific’ medium prior to transplantation into the 
heart [16, 19]. Other cell population that were investigated 
include: fat tissue-derived multipotent stem cells [20] mul-
tipotential cells from bone marrow or skeletal muscle [21] 
somatic stem cells from placental cord blood [22], amniotic 
fluid-derived stem (AFS) cells [23], and cardiac-resident 
progenitor cells that have a heightened predisposition to 
adopt the cardiac muscle fate [24, 25]. In each of these newer 
cases, techniques to isolate and purify these small popula-
tions of potent cells will need to be optimized for clinical 
use. Several researches like Marquette et al. also studied the 
effects of regulatory pathways involved in cardiac develop-
ment and their utility in reprogramming cardiomyocytes to 
aid in cardiac protection or repair and found that thymosin 
b4, a protein involved in cell migration and survival during 
cardiac morphogenesis, may be re-deployed to minimize 
cardiomyocyte loss after cardiac infarction [26]. 
Embryonic Stem Cells  
  ESCs are derived from the inner cell mass of blastocyst 
stage of the embryos; they grow indefinitely in an undiffer-
entiated state while retaining the ability to differentiate to all 
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cell types in the adult body including cardiomyocytes [27]. 
In culture these cells contract rhythmically [28]. Limited 
experience with ESC [29-31] indicates that the potential for 
cardiac repair is greater compared to that of bone marrow 
cells. Even though ESC show promise as a potential new 
therapeutic strategy, several questions need to be answered 
before clinical application of ESC. Assuming they can be 
produced homogeneously in sufficient numbers, the best 
method and site to deliver them would still need to be deter-
mined. Another important issue is graft rejection. Further-
more, the fate of transplanted ESC or their derivatives would 
have to be examined in terms of efficacy and safety. Because 
of unresolved ethical and legal issues, concerns about tu-
morogenicity and arrhythmogenecity of the cells, and the 
need to use allogeneic cells for transplantation, ESC have not 
been investigated broadly and will most likely not be used 
clinically in the near future. 
Umbilical Cord Stem Cells 
  Stem cells isolated from umbilical cord blood have been 
shown to possess a potential for plasticity at least similar to, 
and perhaps even greater than human adult stem cells; also 
their differentiation into cardiac myocytes has been demon-
strated experimentally [22]. As umbilical cord stem cells can 
be obtained without the need to sacrifice an embryo, their 
isolation, use for research purposes and clinical applications 
are not complicated by the ethical and political issues sur-
rounding the debate over embryonic stem cells.  
Amniotic Stem Cells  
 DeCoppi  et al. [23] reported the isolation of a new type 
of stem cell from amniotic fluid that has many characteristics 
of ESC without the ethical concerns. AFS cells seem to rep-
resent an intermediate stage between embryonic and adult 
stem cells in terms of their versatility. They are fully undif-
ferentiated and pluripotent. 
Cardiac Stem Cells  
  Until recently, our perception was that the adult mam-
malian heart was an organ without regenerative capacity. 
However, in the past few years, various reports demonstrated 
the existence of cycling ventricular myocytes both in the 
normal and pathologic adult heart [32]. Moreover, it has 
been shown that, in the regions adjacent to the infarcts from 
patients, 4% of myocyte nuclei expressed the Ki-67 cell pro-
liferation marker. The reentry of myocytes into the cell cycle 
has been quantified as, respectively, 0.08% or 0.03% for the 
zones adjacent or distant to the infarcts [33]. In addition, it 
has also been reported that myocyte hyperplasia contributed 
to the cardiac hypertrophy perhaps due to the proliferation of 
cardiac stem cells (CSC) [33, 35]. These newly described 
stem cells are multipotent, giving rise to endothelial cells, 
smooth muscle cells, and functional cardiomyocytes. In addi-
tion, they supported myocardial regeneration after infarction 
in a rat model [25]. Future research on CSC will help to an-
swer these questions and may provide the means for efficient 
heart regeneration. CSCs are implicated in the normal turn-
over of myocytes, endothelial cells, smooth muscle cells, and 
fibroblasts. Understanding the mechanisms of cardiac ho-
meostasis would offer the extraordinary opportunity to po-
tentiate this naturally occurring process and promote myo-
cardial regeneration following tissue injury. Smith et al.
have shown the feasibility of generating human cardiospheres 
and expanding stem cells from routine endomyocardial bi-
opsy specimens. Human and porcine CSCs can differentiate 
into electrically functional myocytes in vitro. Human CSCs 
injected into mice lead to myocardial regeneration and func-
tional improvement after infarction [34]. 
POSSIBLE MECHANISMS OF ACTION 
  The mechanisms by which stem cells repair damaged 
myocardium or lead to improvement in cardiac function are 
largely unknown, however, the two fundamental activities of 
stem cells are (a) directly or indirectly improve neovascu-
larization (vasculogenesis, angiogenesis and arteriogenesis) 
(b) differentiation into cardiomyocytes and formation of 
myocardial tissue. Functional benefits may also be mediated 
through paracrine secretion of growth factors or cytokines 
which indirectly promote survival of cardiomyocytes by in-
hibition of cardiac apoptosis, and may also lead to mobiliza-
tion of endogenous progenitor cells, all of which affect re-
modeling. A small number of stem cells have been demon-
strated to fuse with the native dysfunctional myocytes and 
even differentiate into cardiac myocytes to augment function 
[36, 37]. So far, a wide range of cell populations have been 
tested and almost all appear to confer benefit which hints at a 
possible involvement of various mechanisms. The extent to 
which these different mechanisms are active may critically 
depend on the cell type and setting. The ultimate success of 
cell therapy will rest on its ability to show clinical efficacy 
rather than on the imputed mechanism [16]. 
CELL DELIVERY  
  The goal of any cell delivery strategy is to transplant suf-
ficient numbers of cells into the myocardial region of interest 
and to achieve maximum retention of cells within that area. 
The three most frequently used routes in clinical setting are 
intracoronary infusion, percutaneous endocardial or direct 
intramyocardial injection during surgery. Intracoronary infu-
sion requires migration through the vessel wall into the dam-
aged tissue. Some cell type like bone marrow-derived and 
blood-derived progenitor cells are known to extravasate and 
migrate to ischemic areas [38], whereas others do not. Satel-
lite cells and mesenchymal cells have been shown to even 
obstruct the microcirculation in higher doses after intra-
arterial administration, leading to embolic myocardial dam-
age [39]. By contrast, direct delivery of progenitor cells into 
scar tissue or areas of hibernating myocardium by catheter or 
surgical based needle injection may generate relative higher 
local retention and less systemic distribution. In experimen-
tal models, intravenous delivery of EPC has been shown to 
improve cardiac function after acute myocardial infarction 
(AMI) [40, 41]. However, homing of cells to noncardiac 
organs limits the clinical applicability of this approach.  
CLINICAL EXPERINCE 
  Among the most important issues being addressed at pre-
sent is identifying the most suitable stem cells for replacing 
muscle mass and examining which mechanisms might con-
tribute to cell-mediated improvement in cardiac function 
after MI such that they could be used additionally or alterna-
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dence that administration of stem cells leads to restoration of 
myocardial function in models of ischemic cardiac damage is 
overwhelming and exciting [16, 41]. Because of this success 
in animal studies, translation into clinical trials started early 
[42]. The most frequently tested cell types in clinical trials 
are skeletal myoblasts and bone-marrow or blood-derived 
progenitor cells. One major pitfall of using autologous cells 
is that the number of functional stem cells is generally de-
pleted with a markedly reduced proliferation potential in the 
elderly and in patients with cardiovascular disease. 
SKELETAL MYOBLASTS  
  Skeletal myoblasts (SM) or satellite cells represent an 
autologous source of progenitor cells that normally lie in a 
quiescent state under the basal membrane of mature muscu-
lar fibers and normally mediate regeneration of skeletal mus-
cle. Studies indicate that it is feasible to establish and expand 
myoblast cultures from skeletal muscle biopsies and to ob-
tain target myoblast numbers (10
9) within 2 to 3 weeks [43]. 
Myoblasts differentiate into myotubes and multiple lines of 
evidence now indicate that these cells retain skeletal muscle 
properties when transplanted into an infarct scar with the 
exception of rare fusion events between skeletal muscle cells 
and cardiomyocytes. Although myotubes remain functionally 
isolated, as they do not couple with resident cardiomyocytes 
electromechanically and therefore do not beat in synchrony 
with the rest of the heart, studies in small and large animal 
models of myocardial infarction have reported beneficial 
effects of myoblast grafting on both systolic and diastolic 
performance [44-47]. Part of the protection seems to result 
from reduced ventricular dilatation, although the complete 
basis for improved mechanical function is currently un-
known. Concern exists about the possible occurrence of seri-
ous arrhythmias, a complication which has been shown only 
in case of SM transplantation [48]. SM might induce ar-
rhythmias by several mechanisms, such as electrotonic 
stimulation of cardiac cells, electrical heterogeneity of action 
potentials, increased nerve sprouting, and local tissue injury 
induced by intramyocardial injection. Since cardiac rhythm 
disturbances have not been seen with other cell types the 
latter mechanism is unlikely. 
Clinical Trials 
  Despite this gap in understanding, myoblasts were the 
first cell type to be used clinically for cardiac repair owing to 
their preclinical efficacy, autologous availability, ability to 
be amplified in vitro, and relatively good survival after im-
plantation. To date, SMs have only been used in trials of 
heart failure, and not for AMI owing to the method of prepa-
ration and route of delivery. The use of SMs in humans was 
first reported by Menasche et al. in a single patient with se-
vere ischemic HF [44]. Autologous SMs were implanted into 
the post infarction scar during coronary artery bypass graft 
(CABG) to remote myocardial areas. Five months later, there 
was evidence of contraction and viability in the grafted scar 
on echocardiography and positron emission tomography 
along with symptomatic improvement. Other nonrandomized 
studies have also showed an improvement in symptoms and 
LV ejection fraction (LVEF) [49-51]. Subsequently, a Phase 
I non-randomized study of transepicardial myoblast trans-
plantation during CABG showed an improvement in symp-
toms and LVEF, as measured by echocardiography. Unfor-
tunately, four out of the ten patients in one trial experienced 
ventricular arrhythmias, necessitating implantable defibrilla-
tors [52]. By contrast, no significant ventricular arrhythmias 
were observed in another Phase I study that recruited 12 pa-
tients and again used the transepicardial approach to deliver 
autologous SM. This study demonstrated a significant in-
crease in LVEF, as well as improved cardiac viability on 
positron emission tomography (PET) at 3 months, suggesting 
that the recovery of myocardial function was associated with 
an increase in functional cell mass [53]. Nevertheless, preop-
erative use of antiarrhythmic therapy or simultaneous im-
plantation of internal defibrillators has been used to address 
these possible safety issues. Percutaneous transendocardial 
route has also been tested and these studies have shown 
promising improvements in cardiac function while also dem-
onstrating the overall safety and feasibility of this approach 
[50, 51, 53, 54]. Finally, SMs have been delivered via the 
coronary venous circulation in an attempt to optimize the 
delivery of these cells to the target tissue and symptomatic 
improvement was seen without significant arrhythmias [55]. 
Dib et al [52] have reported on 30 patients with a history of 
ischemic cardiomyopathy, of whom 24 were treated with SM 
at the time of CABG, whereas the remaining 6 were injected 
with myoblasts during implantation of a left ventricular as-
sist device as a bridge to heart transplantation. The 24 pa-
tients that underwent the cell + CABG procedure were fur-
ther stratified according to a dose-escalating protocol (12 
were divided into four 3-patient groups receiving 1, 3, 10 
and 30 x 10
7, whereas 12 received a fixed dose of 3 x 10
8). 
Like in the previous studies, the LVEF increased from 28% 
to 35% at 1 year (P = 0.02) and to 36% at 2 years (P = 0.01). 
It was also reported that in some patients, PET and magnetic 
resonance imaging (MRI) documented improved viability in 
the cell-injected scar tissue. The results of the Phase II, first 
randomized, placebo-controlled trial Myoblast Autologous 
Grafting in Ischemic Cardiomyopathy (MAGIC) included 97 
patients at 24 medical centers in Europe undergoing CABG 
after MI with moderate to severe LV systolic dysfunction. 
All patients received an implanted cardioverter defibrillator. 
The study was ended early, since the treatment was not supe-
rior to placebo on the primary endpoints of improvement in 
regional contractility or global function. A significant de-
crease was documented of LV volumes, a finding which 
might be clinically relevant since ventricular dimensions are 
predictors of outcome and long-term follow-up data are 
awaited [56]. 
PROGENITOR CELLS 
  The bone marrow is known to be an abundant reservoir 
for many adult stem cells, and bone marrow–derived stem 
cells (BMC) have been used to treat hematologic disorders 
for decades. Recent reports have demonstrated that BMC are 
able to traverse cell lineage boundaries and transdifferentiate 
into hepatocytes, endothelial cells, skeletal muscle, and neu-
rons upon proper stimulation [57-59]. Although the ability of 
BMC to transdifferentiate into cardiomyocytes remains 
highly controversial, much of the recent progress in regen-
erative cardiovascular research, both in animals and human 
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hematopoietic stem cells ( HSC), mesenchymal stem cells 
(MSC), and endothelial progenitor cells (EPC).  
Hematopoietic Stem Cells  
  HSC can be isolated from bone marrow cells through 
selective sorting for a particular set of surface receptors 
which are lineage negative (Lin) and positive for stem cell 
markers (c-kit, Sca-1) [60,61] and represent the prototypical 
adult stem cell population. The ability of HSC to reconstitute 
the hematopoietic system of a myeloablated host led to the 
first clinical application of adult stem cells more than 3 dec-
ades ago [62]. Despite the failure of studies to definitely 
prove differentiation of HSC into cardiomyocytes in vitro,
several studies in mice have demonstrated the potential of 
HSC to differentiate into cardiomyocytes or vascular cells 
after cardiac injury in vivo [42, 63, 64]. 
Mesenchymal Stem Cells 
  Within the bone marrow stroma resides a subset of non-
hematopoietic cells that have the potential to differentiate 
into cells of mesenchymal origin [65, 66]. These MSC repre-
sent approximately 0.001% to 0.01% of the total nucleated 
marrow cell population. Immunophenotypically, MSC lack 
the typical hematopoietic antigens (c-kit, CD45, CD34, 
CD14) but express specific adhesion molecules (AL-
CAM/CD44) and antigens (SH2/SH3/SH4/STRO-1) [67, 
68]. At first, MSC were thought to contribute solely to the 
formation of the stromal microenvironment in the bone mar-
row and maintain HSC survival and function. However, sub-
sequent studies have suggested that MSC are themselves 
capable of multipotency, with differentiation into chondro-
cytes, osteoblasts, astrocytes, neurons, skeletal muscle, and 
notably, cardiomyocytes [69-71]. 
Endothelial Progenitor Cells 
  EPC represent a subset of hematopoietic stem cells that 
are able to acquire an endothelial phenotype in vitro [72-75]. 
EPC express the hematopoietic stem cell markers CD133 
and CD34 and the endothelial marker Flk-1 (VEGFR-2) 
[74]. EPC can be isolated directly from the bone marrow or 
from the peripheral circulation. 
Clinical Trials 
  A number of clinical studies employing progenitor cells 
have been performed to date with only few randomized, con-
trolled trials [40, 42, 76]. The largest study of cardiac cell 
therapy reported by Schachinger et al. [77], the Reinfusion 
of Enriched Progenitor Cells and Infarct Remodeling in AMI 
(REPAIR-AMI) trial, is a multicenter trial of intracoronary 
infusion of BMC after successful PCI for AMI involving 204 
patients. At 4 months, the absolute improvement in LVEF, 
measured by angiography, was greater among patients 
treated with BMC than among those given placebo (5.5% vs.
3.0%, P = 0.01). Subgroup analysis suggested that the bene-
fit was greatest in patients with the worst LVEF at baseline. 
This double-blind, randomized and placebo-controlled trial 
provides the best evidence yet for beneficial effects of BMC 
after AMI. Enthusiasm is somewhat tempered by the modest 
size of the effect and by a recent report from the bone mar-
row transfer to enhance ST-elevation infarct regeneration 
(BOOST) trial that the relative improvement in LVEF after 
infusion of BMC at 6 months, as compared with no infusion, 
was no longer significant at 18 months, suggesting that the 
main effect was an acceleration of recovery [78]. While data 
on ventricular function at 1 year are not available for RE-
PAIR-AMI trial, it could be demonstrated that intracoronary 
administration of BMCs is associated with a significant re-
duction of the occurrence of major adverse cardiovascular 
events after AMI including death, myocardial infarction, or 
necessity for revascularization and rehospitalization for HF 
compared to patients receiving placebo.  
  In contrast, in the smaller Autologous Stem-cell Trans-
plantation in AMI (ASTAMI) trial involving three noninva-
sive imaging methods, Lunde et al. [79] did not find a sig-
nificant improvement in LVEF at 6 months in the mononu-
clear BMC group, as compared with the control group. 
Technical differences in the characteristics or handling of the 
Table 1. Selected Clinical Trials of Autologous Skeletal Myoblasts in Cardiomyopathy
Study Design(n)  Cell  type  Route  Follow-up Outcomes 
Menasche et al. (2003)  Series (10)  Myoblasts  Epicardial 
During CABG
5
5-17.5 months  Improved NYHA
Improved LVEF
Herreros et al.
(2003) 
Series (12)  Myoblasts  Epicadial 
During CABG
5
3 months  Improved LVEF
1
Simniak et al.
(2004) 
Series (10)  Myoblasts  Epicadial 
During CABG
5
6 months  Improved LVEF
1
Dib et al.
(2005) 
Series (30)  Myoblasts  Epicadial CABG
5+LVAD 2 years  Improved LVEF
1
MAGIC 
(2006) 
RCT
4, double blind  Myoblasts  Epicadial 
During CABG
5
Early termination  No effect on EF 
+ LV remodeling 
LVEF, Left ventricular ejection fraction; LVAD, left ventricular assist device; NYHA, New York Heart Association functional class; 
4RCT, randomized clinical trial; 
5CABG, 
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infused BMC might explain the different outcome. Janssens 
et al. [80] also did not detect an improvement in global ven-
tricular function at 4 months in the BMC group as compared 
with the control group, although infarct size was reduced and 
regional wall motion was improved in the BMC group. The 
identification of features of BMC preparations and of pa-
tients that are predictive of a favorable response should help 
to resolve these discrepancies and to focus future trials. 
Given the relatively small number of events, this result will 
require replication in larger cohorts. However, it reinforces 
the message that BMC infusion is not only feasible but also 
safe, and it raises the possibility that clinical benefits may 
exceed the modest improvement seen in ventricular function. 
These studies provide a realistic perspective on this approach 
while leaving room for cautious optimism and underscoring 
the need for further studies.  
  The Transplantation of Progenitor Cells and Recovery of 
LV Function in patients with Chronic ischemic Heart Dis-
ease (TOPCARE-CHD) trial by Assmus et al. [81] evaluated 
the effects of BMC derived from circulating blood in patients 
with chronic ventricular dysfunction. In this randomized, 
crossover trial, the absolute change in LVEF was signifi-
cantly greater among patients receiving BMC. The groups 
received the other type of cell in the next phase of the trial, 
but the result was independent of the order in which the cells 
were given, suggesting that the BMC effect is somewhat 
specific. Which quantitative or qualitative differences in the 
cell populations account for their different effects is cur-
rently unknown. Although the benefit observed after BMC 
infusion was modest (an increase in LVEF by 2.9% points), 
it is remarkable that any benefit was seen in these patients, 
who were studied on average more than 6 years after infarc-
tion and who were already receiving optimal medical care. 
The TOPCARE- CHD trial suggests that BMC can have 
effects beyond simple acceleration of healing after infarc-
tion. Whether repeated infusions would yield additive bene-
fits and whether these benefits would persist will be impor-
tant questions for future trials. Assmus hereby confirms the 
data by Willerson et al., who described for the first time that 
injection of bone marrow cells, is not only safe but also in-
creases exercise capacity in patients with ischemic cardio-
myopathy who were heart transplant candidates [82]. 
CARDIAC TISSUE ENGINEERING 
  A different concept in cardiac regeneration is grafting ex
vivo engineered heart muscle. This approach may theoreti-
cally allow complete replacement of diseased myocardium or 
reconstitution of cardiac malformations. Large myocardial 
patches depend critically on metabolic supply, and thus vas-
cularization is crucial. Not only structural but also electrical 
integration into the host myocardium is necessary. Zimmer-
mann  et al. [83] have developed a methodology to create 
engineered heart tissue (EHT) from neonatal rat heart cells, 
liquid collagen I and Matrigel as well as growth supple-
ments, reconstituted in circular molds and subjected to me-
chanical strain. Under these conditions, cardiac organoids 
developed spontaneously and showed contractile as well as 
electrophysiologic properties of working myocardium. Im-
plantation experiments in healthy rats showed survival, and 
signs of terminal differentiation of EHT grafts. In a rodent 
model of myocardial ischemia EHTs integrate and electri-
cally couple to host myocardium display strong vasculariza-
tion and exert beneficial effects on systolic and diastolic LV 
function without inducing arrhythmias. This observation is 
not trivial given the fact that EHTs are not homogeneous 
heart muscles but organoids consisting of muscle strands, 
primitive capillaries, fibroblasts, smooth muscle cells and 
macrophages in a collagen matrix. Although complete rever-
sal of myocardial dysfunction after EHT engraftment was 
not observed, this study can serve as a proof of principle for 
a tissue engineering approach in repair of cardiac muscle. 
However, cardiac tissue engineering is still in its infancy 
with several important questions that remain in terms of po-
tential clinical applications [83].  
Table 2. Selected Clinical Trials of Bone Marrow-Derived Stem Cells 
Study Design(n)  Cell  type Route Outcomes 
BOOST  RCT, open label (60)  BM-MNC
1 Intracoronary Improvement  of 
LVEF
5 at 6 months 
TOPCARE-AMI Randomized  (59)  BM-MNC
1vs. CPC
2 Intracoronary  Improved LVEF
5 and per-
fusion 
Janssens et al.  RCT, double blind (67)  BM-MNC
1  Intracoronary  Reduced infract size 
ASTAMI  RCT, double blind (100)  BM-MNC
1 Intracoronary No  benefit 
REPAIR-AMI  RCT, double blind (204)  BM-MNC
1 Intracoronary  Improved  LVEF
5
REVIVAL-2  RCT, double blind (114)  G-CSF
6 and PBSC
3  Mobilization  No  effect on LVEF
5
TOPCARE-CHD  RCT, cross over (75)  BM-MNC
1 vs. CPC
2 Intracoronary  Improvement  of  LVEF
5
MAGIC Cell-3-DES
4 RCT  (96) G-CSF
6 vs. G-CSF
6 + 
PBSC
3
Intracoronary Improvement  of  LVEF
5
1BM-MNC, Bone marrow mononuclear cell; 
2CPC, circulating progenitor cell; 
3PBSC, peripheral bone marrow stem cells; 
4DES, Drug-eluting stent; 
5 LVEF, Left ventricular ejec-
tion fraction; 
6G-CSF, Granulocyte Colony stimulating factor 78 Current Cardiology Reviews, 2008, Vol. 4, No. 2 Pendyala et al. 
 Ott  et al. engineered a biocompatible cardiac extra cellu-
lar matrix scaffold with perfusable vascular tree, patent 
valves and four chamber geometry templates by perfusion 
decellularization. Reseeding of decellularized heart was done 
by intramural injection of cardiac derived cells and by perfu-
sion of endothelial cells in vascular conduits. The recellular-
ized construct was functional and drug responsive for 8 days 
of culture. With sufficient maturation, and given the further 
ability to reseed its inherent vascular architecture and interior 
with endothelial cells, this organ could become transplant-
able either in part or as entire donor heart in end stage HF 
[84]. 
CHALLENGES AND FUTURE  
  Stem cell treatment of the heart has not been shown to 
lead to the development of large caliber coronary vessels but 
rather to capillaries and arterioles by both angiogenesis and 
vasculogenesis. Therefore, stem cells are either used as ad-
junct to PCI or CABG or in patients with angiographically 
proven CAD without viable percutaneous or surgical treat-
ment options. These include patients with diffuse small ves-
sel disease, in-stent restenosis, and chronic total occlusion. It 
has been estimated that over 100,000 patients may be in this 
‘no-option’ group in the US each year [85]. Many alternative 
approaches have been tested in the past, including transmyo-
cardial laser revascularization, active and passive cardiomy-
oplasty, gene therapy, surgical ventricular remodeling, coro-
nary endarterectomy and growth factor application, most of 
which yielded no or very little improvement at best. 
  The observation that stem cells might augment and assist 
cardiac regeneration has not only caused debates, but also 
led to enormous excitement and intense investigations in the 
rapidly advancing field of cellular cardiomyoplasty. Knowl-
edge created by basic scientists and clinicians, developmen-
tal biologists and engineers has led to a better understanding 
of the molecular signals and cues of cardiac regeneration, 
cardiopoiesis and cardiomyogenesis and provided us with 
greater insights into human biology. The use of stem cells 
and progenitor cells for therapeutic intervention in cardio-
vascular disease holds not only great promise, but also har-
bors significant controversy.  
  Despite the advances that have been made in this broad 
area, it is important to emphasize that there are still funda-
mental questions that need to be addressed both experimen-
tally and clinically regarding potential features of cell repair. 
The most eminent unresolved issues are; cell delivery, opti-
mization of cell retention, distribution, the best route of de-
livery, time of transplantation, cell type, cell number, and 
viability of grafted cells. Strategies to genetically modify 
stem cells aimed to improve survival have been employed 
[86]. Hill et al. [87] observed a strong correlation between 
the number of circulating EPCs and the subjects’ combined 
Framingham cardiovascular risk factor score. Therefore, 
with the onset of disease (or the presence of risk factors), the 
relevant cells appear to decrease in number and lose their 
reparative function. Despite the high number of stem cell 
studies performed, there is still no consensus on the opti-
mal/minimal cell number required to achieve any effect. In 
fact in a few clinical studies, investigators used a cell number 
in clinical trial that would barely suffice to treat a mouse 
heart [82]. While functional improvement of the infarcted 
heart by stem cells has been recognized even by fierce disbe-
lievers in cellular cardiomyoplasty, the way by which stem 
cells regenerate the heart are not yet elucidated. A surpris-
ingly wide range of nonmyogenic cell types improves ven-
tricular function, suggesting that benefit may result in part 
from mechanisms that are distinct from true myocardial re-
generation [88, 89]. Future trials should be randomized, con-
trolled and designed and powered to examine clinical end 
points and patients should be followed over the long term 
and for both beneficial and adverse effects.  
  Considerable work needs to be done before cell based 
therapy can be used routinely in the clinical setting for peo-
ple. We are confident, however, that the exciting approach of 
cellular cardiomypoplasty will lead to an effective clinical 
therapy and thus has the potential to improve the health of 
millions of people worldwide each year. 
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